UTMD · Utah Medical Products Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.72M | - | $9.81M | $9.95M | $9.71M | - | $10.01M | $10.40M | $11.34M | - |
| Cost of Revenue | $3.44M | - | $4.21M | $4.36M | $4.17M | - | $4.20M | $4.15M | $4.57M | - |
| Gross Profit | $5.28M | - | $5.60M | $5.59M | $5.54M | - | $5.80M | $6.25M | $6.77M | - |
| R&D | $154.0K | - | $167.0K | $135.0K | $154.0K | - | $172.0K | $255.0K | $266.0K | - |
| SG&A | $2.56M | - | $2.83M | $2.26M | $2.23M | - | $2.29M | $2.56M | $2.62M | - |
| Total Operating Expenses | $2.72M | - | $2.99M | $2.40M | $2.38M | - | $2.46M | $2.81M | $2.88M | - |
| D&A | $211.0K | - | - | - | $200.0K | - | - | - | $156.0K | - |
| Operating Income | $2.56M | - | $2.61M | $3.20M | $3.15M | $16.80M | $3.34M | $3.44M | $3.88M | $20.09M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $578.0K | - | $678.0K | $788.0K | $817.0K | $2.93M | $616.0K | $758.0K | $842.0K | $3.45M |
| Net Income | $2.60M | - | $2.63M | $3.05M | $3.04M | - | $3.56M | $3.45M | $3.96M | - |
| EPS - Basic | $0.82 | - | $0.82 | $0.94 | $0.92 | - | $1.02 | $0.98 | $1.09 | - |
| EPS - Diluted | $0.82 | - | $0.82 | $0.94 | $0.92 | - | $1.02 | $0.98 | $1.09 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $87.41M | $85.76M | $84.27M | $82.18M | $83.33M | $82.98M | $88.45M | $89.22M | $93.81M | $92.87M |
| Accounts Receivable | $3.64M | $3.52M | $3.73M | $3.63M | $3.94M | $4.09M | $3.72M | $3.67M | $3.59M | $3.39M |
| Inventory | $8.72M | $7.93M | $8.12M | $8.23M | $8.65M | $8.81M | $9.11M | $9.06M | $9.24M | $9.58M |
| Accounts Payable | $1.19M | $911.0K | $768.0K | $737.0K | $914.0K | $696.0K | $999.0K | $834.0K | $998.0K | $769.0K |
| Current Assets | $100.38M | $97.74M | $96.53M | $94.38M | $96.40M | $96.33M | $101.66M | $102.32M | $107.15M | $106.27M |
| Total Assets | $124.38M | $122.54M | $121.97M | $120.80M | $122.52M | $122.54M | $129.69M | $130.03M | $135.44M | $135.46M |
| Current Liabilities | $3.50M | $2.60M | $3.01M | $2.25M | $4.32M | $3.76M | $3.44M | $3.94M | $5.47M | $4.71M |
| Long-term Debt | - | $0 | - | - | - | $0 | - | - | - | $0 |
| Total Liabilities | $4.01M | $3.27M | $3.72M | $3.27M | $5.47M | $5.11M | $5.50M | $5.98M | $7.70M | $7.14M |
| Stockholders' Equity | $120.37M | $119.27M | $118.25M | $117.53M | $117.05M | $117.43M | $124.20M | $124.05M | $127.74M | $128.31M |
| Retained Earnings | $130.26M | $128.65M | $127.96M | $126.86M | $128.20M | $129.30M | $134.05M | $135.34M | $139.00M | $138.34M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.11M | - | - | - | $4.46M | - | - | - | $5.28M | - |
| Investing Cash Flow | ($130.0K) | - | - | - | ($184.0K) | - | - | - | $5.0K | - |
| Financing Cash Flow | ($1.12M) | - | - | - | ($4.24M) | - | - | - | ($3.98M) | - |
| CapEx | $130.0K | - | - | - | $184.0K | - | - | - | $22.0K | - |
| Free Cash Flow | $2.98M | - | - | - | $4.28M | - | - | - | $5.25M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 60.6% | - | 57.1% | 56.2% | 57.0% | - | 58.0% | 60.1% | 59.7% | - |
| Operating margin | 29.4% | - | 26.6% | 32.1% | 32.5% | - | 33.4% | 33.1% | 34.2% | - |
| EBITDA margin | 31.8% | - | - | - | 34.5% | - | - | - | 35.6% | - |
| Net margin | 29.9% | - | 26.8% | 30.6% | 31.3% | - | 35.6% | 33.2% | 34.9% | - |
| Free cash flow margin | 34.2% | - | - | - | 44.1% | - | - | - | 46.3% | - |
| FCF / Net income | 1.14 | - | - | - | 1.41 | - | - | - | 1.33 | - |
| R&D / Revenue | 1.8% | - | 1.7% | 1.4% | 1.6% | - | 1.7% | 2.5% | 2.3% | - |
| SG&A / Revenue | 29.4% | - | 28.8% | 22.7% | 23.0% | - | 22.9% | 24.6% | 23.1% | - |
| Effective tax rate | 18.2% | - | 20.5% | 20.5% | 21.2% | - | 14.7% | 18.0% | 17.5% | - |
| Return on assets | 2.1% | - | 2.2% | 2.5% | 2.5% | - | 2.7% | 2.7% | 2.9% | - |
| Return on equity | 2.2% | - | 2.2% | 2.6% | 2.6% | - | 2.9% | 2.8% | 3.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 28.64 | 37.62 | 32.06 | 41.87 | 22.29 | 25.64 | 29.59 | 25.98 | 19.57 | 22.56 |
| Quick ratio | 26.15 | 34.57 | 29.36 | 38.22 | 20.29 | 23.29 | 26.94 | 23.68 | 17.89 | 20.53 |
| Cash ratio | 24.94 | 33.01 | 27.99 | 36.46 | 19.27 | 22.09 | 25.75 | 22.65 | 17.14 | 19.72 |
| Leverage | ||||||||||
| Debt / Equity | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 |
| Debt / Assets | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.03 | 1.03 | 1.03 | 1.03 | 1.05 | 1.04 | 1.04 | 1.05 | 1.06 | 1.06 |
| Liabilities / Assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.05 | 0.06 | 0.05 |
| Efficiency | ||||||||||
| Asset turnover | 0.07 | - | 0.08 | 0.08 | 0.08 | - | 0.08 | 0.08 | 0.08 | - |
| Inventory turnover | 0.39 | - | 0.52 | 0.53 | 0.48 | - | 0.46 | 0.46 | 0.50 | - |
| Days sales outstanding | 152d | - | 139d | 133d | 148d | - | 136d | 129d | 116d | - |
| Days inventory outstanding | 925d | - | 704d | 690d | 757d | - | 791d | 797d | 737d | - |
| Days payable outstanding | 127d | - | 67d | 62d | 80d | - | 87d | 73d | 80d | - |
| Cash conversion cycle | 951d | - | 776d | 761d | 825d | - | 840d | 853d | 773d | - |
| Valuation | ||||||||||
| P / E | 75.6x | - | 76.8x | 60.6x | 60.9x | - | 65.6x | 68.2x | 65.2x | - |
| P / B | 1.6x | - | 1.7x | 1.6x | 1.6x | - | 1.9x | 1.9x | 2.0x | - |
| P / S | 22.6x | - | 20.6x | 18.6x | 19.1x | - | 23.3x | 22.7x | 22.7x | - |
| EV / EBITDA | 39.6x | - | - | - | 30.5x | - | - | - | 40.5x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -10.2% | - | -1.9% | -4.3% | -14.4% | - | -20.0% | -19.2% | -9.4% | - |
| Revenue CAGR (3y) | -11.4% | - | -8.8% | -9.5% | -7.6% | - | -7.3% | -6.2% | 1.1% | - |
| Revenue CAGR (5y) | -4.5% | - | -1.3% | 2.5% | -2.3% | - | -4.3% | -2.6% | 1.1% | - |
| Gross profit growth (YoY) | -4.6% | - | -3.4% | -10.5% | -18.1% | - | -21.2% | -19.2% | -13.7% | - |
| Operating income growth (YoY) | -18.6% | - | -21.9% | -7.0% | -18.8% | -16.4% | -15.8% | -22.3% | -12.5% | - |
| Net income growth (YoY) | -14.4% | - | -26.2% | -11.7% | -23.1% | - | -9.5% | -17.8% | -6.1% | - |
| EPS growth (YoY) | -10.9% | - | -19.6% | -4.1% | -15.6% | - | -5.6% | -14.8% | -6.0% | - |
| EPS CAGR (3y) | -10.9% | - | -11.4% | -5.7% | -1.4% | - | -3.9% | 1.4% | 9.5% | - |
| EPS CAGR (5y) | -0.2% | - | 0.5% | 21.2% | 1.8% | - | 0.6% | 0.8% | 5.3% | - |
| FCF growth (YoY) | -30.4% | - | - | - | -18.5% | - | - | - | -23.5% | - |
| FCF CAGR (5y) | -11.6% | - | - | - | -3.9% | - | - | - | 9.4% | - |
| Book value growth (YoY) | 2.8% | 1.6% | -4.8% | -5.3% | -8.4% | -8.5% | 0.4% | 1.9% | 8.2% | 12.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$38.52M totalGynecology Electrosurgery Urology$19.72M · 51.2%
Neonatal$8.01M · 20.8%
Blood Pressure Monitoring And Accessories$6.79M · 17.6%
Obstetrics$4.00M · 10.4%
Geographic
$54.28M totalGlobal$38.52M · 71.0%
Ous$15.76M · 29.0%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing UTAH MEDICAL PRODUCTS INC against the 5 most active filers in the same SIC group.
Dividends
$1.23/share trailing 12 months · +1.7% YoY
| Ex-date | Per share |
|---|---|
| Mar 17, 2026 | $0.3100 |
| Dec 16, 2025 | $0.3100 |
| Sep 17, 2025 | $0.3050 |
| Jun 16, 2025 | $0.3050 |
| Mar 14, 2025 | $0.3050 |
| Dec 16, 2024 | $0.3050 |
| Sep 20, 2024 | $0.3000 |
| Jun 14, 2024 | $0.3000 |
| Mar 14, 2024 | $0.3000 |
| Dec 14, 2023 | $0.3000 |
| Sep 14, 2023 | $0.2950 |
| Jun 15, 2023 | $0.2950 |
| Mar 16, 2023 | $0.2950 |
| Dec 15, 2022 | $0.2950 |
| Sep 15, 2022 | $0.2900 |
| Jun 16, 2022 | $0.2900 |
| Mar 17, 2022 | $0.2900 |
| Dec 14, 2021 | $2.0000 |
| Sep 15, 2021 | $0.2850 |
| Jun 14, 2021 | $0.2850 |
| Mar 16, 2021 | $0.2850 |
| Dec 14, 2020 | $0.2850 |
| Sep 14, 2020 | $0.2800 |
| Jun 16, 2020 | $0.2800 |